Dissecting How Xenobiotics Act as Adjuvants for Oral Allergic Sensitization
剖析异生素如何作为口腔过敏致敏佐剂
基本信息
- 批准号:10615112
- 负责人:
- 金额:$ 57.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-24 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcetaminophenAdjuvantAffectAllergicAllergic DiseaseAmericanAnalgesic and AntipyreticAnalgesicsAntigen PresentationAntigensCell NucleusCellsChemical StructureChemicalsChildCholera ToxinCollaborationsCysteineDataDendritic CellsDevelopmentDissectionDoseDrug usageEnvironmentEnvironmental ExposureEpithelial CellsErythroidEtiologyExposure toFatty acid glycerol estersFoodFood HypersensitivityFood PreservativesGeneticHealth PolicyHigh PrevalenceHumanHydroquinonesHypersensitivityIbuprofenImmune responseIncidenceIngestionIntestinesKnock-outLeadLinkMediatingMedicineModelingModernizationMusNon-Steroidal Anti-Inflammatory AgentsNuclearOralOvalbuminPTGS2 genePathway interactionsPersonsPharmaceutical PreparationsPredispositionPrevalenceProcessProductionPropertyPublic HealthRoleSeveritiesSignal TransductionSourceSpecificityTestingTimeWorkXenobioticsadductallergic responsedosagedrug actionfood antigenfood consumptiongut microbiomeintestinal epitheliummanmicrobiotanovelnovel therapeuticsnuclear factor-erythroid 2oral tolerancepharmacologicreceptorsensorurban setting
项目摘要
PROJECT SUMMARY
Food allergies have been increasing at an exponential rate since 1960 for unknown reasons. We hypothesized
that modern xenobiotics that were widely introduced into the modern environment may be acting as allergic
adjuvants to break oral tolerance and cause allergy. This proposal will explore how certain non-steroidal anti-
inflammatory drugs (NSAIDs) are sufficient for oral allergic sensitization. The proposal will test the overarching
hypothesis that adjuvant NSAIDs are activators of the xenobiotic sensor, Nuclear factor erythroid 2-related
factor 2 (NRF2), in intestinal epithelial cells, which release IL33 to initiate the allergic response to coincident
food antigen. We will use a combination of genetic, pharmacologic, and mass spectroscopic approaches to
rigorously test this hypothesis. If confirmed, our work has major implications for why allergies are increasing
and could lead to new public health policies and novel therapies for the management of allergic diseases.
项目总结
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Wang其他文献
Andrew Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Wang', 18)}}的其他基金
The Role of the Adrb3/IL6 Axis in the Impact of Psychosocial Stress on Lupus Pathogenesis
Adrb3/IL6 轴在心理社会压力对狼疮发病机制影响中的作用
- 批准号:
10557799 - 财政年份:2022
- 资助金额:
$ 57.47万 - 项目类别:
The Role of the Adrb3/IL6 Axis in the Impact of Psychosocial Stress on Lupus Pathogenesis
Adrb3/IL6 轴在心理社会压力对狼疮发病机制影响中的作用
- 批准号:
10342034 - 财政年份:2022
- 资助金额:
$ 57.47万 - 项目类别:
Dissecting How Xenobiotics Act as Adjuvants for Oral Allergic Sensitization
剖析异生素如何作为口腔过敏致敏佐剂
- 批准号:
10409840 - 财政年份:2021
- 资助金额:
$ 57.47万 - 项目类别:
Dissecting How Xenobiotics Act as Adjuvants for Oral Allergic Sensitization
剖析异生素如何作为口腔过敏致敏佐剂
- 批准号:
10272937 - 财政年份:2021
- 资助金额:
$ 57.47万 - 项目类别:
Regulation of Metabolic Programs for Host Tolerance to Inflammation
调节宿主对炎症的耐受性的代谢程序
- 批准号:
9224559 - 财政年份:2017
- 资助金额:
$ 57.47万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 57.47万 - 项目类别: